share_log

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

这些股票在Biogen-Eisai出人意料的阿尔茨海默氏症试验获胜后受到关注
Benzinga Real-time News ·  2022/09/28 16:10  · 市场
One of the most-watched Alzheimer's therapies in the clinic, Biogen(BIIB.US) Inc-Eisai Limited's (OTC:ESALY) experimental lecanemab reduced clinical decline on the scale by 27% compared to the placebo at 18 months in early Alzheimer's. In July 2022, the FDA accepted the marketing application for lecanemab under the accelerated approval pathway and granted a Priority Review. The PDUFA date is Jan. 6, 2023. Several stocks related to Alzheimer's programs are gaining. SVB Leerink said these positive results would reinvigorate the Alzheimer's space.
这是临床上最受关注的阿尔茨海默氏症疗法之一,Biogen(BIIB.US)INC-卫材有限公司的(场外交易代码:ESALY)在18个月的早期阿尔茨海默病患者中,试验性lecanemab与安慰剂相比,减少了27%的临床下降。 2022年7月,FDA在加速审批路径下接受了lecanemab的上市申请,并批准了优先审查。PDUFA的日期是2023年1月6日。 与阿尔茨海默氏症项目相关的几只股票正在上涨。SVB Leerink表示,这些积极的结果将使阿尔茨海默氏症领域重新焕发活力。
Eli Lilly and Co(LLY.US) - Market cap: $317 billion.
礼来(LLY美国)-市值:3170亿美元。
Positive readthrough is expected from its...
预计2023...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发